PRECIOS: Es un clamor...

"Kidney cancer drugs could be produced for about a tenth of their current cost", Rawlins said. 'Pharmaceutical companies have enjoyed double-digit growth year on year and they are out to sustain that, not least because their senior management's earnings are related to the share price. It's not in their interests to take less profit, personally as well as from the point of view of the business. All these perverse incentives drive the price up.

Tendrá que ver esto con nuestro post de días pasados...?

'The other thing we have to pay for is the costs of marketing.

Marketing costs generally are about twice the spend on research and development.'

Sir Michael Rawlings es chairman del National Institute of Health & Clinical Excellence (NICE) desde su formación en 1999.


Mas...

The number of brand-name drugs with increases of 100% or more could double this year from four years ago, researchers from the University of Minnesota say

EXAMPLES OF RISING DRUG PRICES

Researchers found a growing number of drugs with one-time price increases of 100% or more. Some examples based on average wholesale prices:

Drug	Condition	Company	Price before	Price after	% increase
Cosmegen	Wilms' tumor	Ovation	$16.79	$593.75	3,436%
Indocin IV	Heart problem in premature babies	Ovation	$136.10	$1,875	1,278%
Acthar	Infantile spasms	Questcor	$1,650	$23,269	1,310%

Mas...